. Author manuscript; available in PMC: 2012 Dec 8.

Published in final edited form as: Cancer Lett. 2011 Aug 6;311(2):219–229. doi: 10.1016/j.canlet.2011.07.023

Table 1.

In vivo antitumor activity

Treatments	MSC¹ 0.2mg/d	Irinotecan² 100mg/kg	Concurrent³ Combination	Sequential⁴ Combination
FaDu response rate⁵	0%	35%	40%	100%^***
A253 response rate	0%	10%	10%	40%^***

MSC dose (0.2 mg/d × 28)

Irinotecan (100mg/kg/wk × 4)

MSC + irinotecan

⁴

MSC 7d prior to and then concurrently with irinotecan

⁵

Complete Response (CR): no detectable tumor at the site of transplant for up to 3 months after termination of treatments

^***

p<0.001when compared with other groups